<DOC>
	<DOCNO>NCT01698775</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety omarigliptin participant type 2 diabetes mellitus moderate severe chronic renal insufficiency end stage renal disease dialysis inadequate glycemic control . The primary hypothesis study omarigliptin compare placebo produce great reduction glycosylated hemoglobin ( A1C ) 24 week .</brief_summary>
	<brief_title>A Study Omarigliptin ( MK-3102 ) Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease Kidney Failure Dialysis ( MK-3102-019 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Type 2 diabetes mellitus least 30 year age Moderate severe chronic renal insufficiency end stage renal disease dialysis Meet one follow criterion : 1. currently antihyperglycemic agent ( AHA ) A1C &gt; =7 % &lt; =10 % screen 2. currently single oral AHA lowdose dual oral combination AHA A1C &gt; =6.5 % &lt; =9 % screen 3. currently stable insulin regimen ( &gt; = 15 U/day ) &gt; = 10 week , oral AHA , A1C &gt; =7.5 % &lt; =10 % FPG &gt; 130 mg/dL screening ( 1 ) Male ; ( 2 ) female reproductive potential ; ( 3 ) female reproductive potential agrees remain abstinent use alone conjunction partner 2 method contraception prevent pregnancy study 28 day last dose study drug History type 1 diabetes mellitus history ketoacidosis Treated incretin mimetic thiazolidinedione ( TZD ) within 12 week prior screen omarigliptin time prior study participation History hypersensitivity dipeptidyl peptidase IV ( DPP4 ) inhibitor History intolerance hypersensitivity glipizide insulin glargine contraindication glipizide insulin glargine On weight loss program maintenance phase , weight loss medication past 6 month , undergone bariatric surgery within 12 month prior study participation Undergone surgical procedure within 4 week prior screen plan major surgery trial On likely require treatment &gt; =2 consecutive week repeat course corticosteroid ( note : inhale , nasal topical corticosteroid permit ) Currently treat hyperthyroidism thyroid replacement therapy stable dose least 6 week If dialysis , regularly adhere dialysis schedule Diagnosis congestive heart failure New York Heart Association ( NYHA ) Class IV Medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Human immunodeficiency virus ( HIV ) New worsen coronary heart disease , congestive heart failure , myocardial infarction , unstable angina , coronary artery intervention , stroke , transient ischemic neurological disorder within past 3 month Poorly control hypertension Severe active peripheral vascular disease History malignancy &lt; =5 year prior study participation , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer Clinically important hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Positive pregnancy test Pregnant breastfeeding , expect conceive donate egg trial , include 28 day follow last dose study drug User recreational illicit drug recent history drug abuse routinely consume &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week , engage binge drinking</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>